ArticleNature2025
Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Could AAV-vectored delivery of broadly neutralizing antibodies (bNAbs) reduce virologic failure in children diagnosed with perinatal HIV?Human vaccines & immunotherapeutics · 2026Review
- Long-term depletion of KIR3DL01+ NK cells by adeno-associated viral-vectored antibody delivery alters chronic SIV infection.PLoS pathogens · 2026Article
- Scientific synergy between prophylactic and therapeutic HIV vaccines-prevention and cure.NPJ vaccines · 2026Article
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- Co-delivered PD-L1 rescues the protective efficacy mediated by an AAV-expressed HIV-1 bNAb.bioRxiv : the preprint server for biology · 2026Article
- Overcoming host immune responses to an AAV-delivered HIV-1 bNAb in rhesus macaques mediated by co-delivery of PD-L1.bioRxiv : the preprint server for biology · 2026Article
- Engineering challenges and translational opportunities in emerging gene delivery platforms.Nature biomedical engineering · 2026Review
- Review
- Durable protection against SIV challenge by adeno-associated virus delivery of Env-specific antibodies.bioRxiv : the preprint server for biology · 2026Article
- HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice.Immunity · 2026Article
- Structural basis for childhood antibody recognition of the human metapneumovirus fusion protein.Nature communications · 2025Article
- AAV-mediated gene therapy for the CNS: The case for early treatment.Molecular therapy. Methods & clinical development · 2025Article
- Structural Basis for Childhood Antibody Recognition of The Human Metapneumovirus Fusion Protein.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Amir ArdeshirCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-4330-4659
Daniel O'HaganDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA.
Isha MehtaCenter for Systems Immunology, Departments of Immunology and Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-6009-0787
Siddhartha ShandilyaDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA.ORCID 0000-0002-9179-5878
Lincoln L J HopkinsCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-3874-3585
Lourdes AdamsonCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Marcelo J KurodaCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.
Patricia A HahnDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA.ORCID 0000-0002-4338-4660
Lucas A B da CostaDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA.
Sebastian P FuchsDepartment of Pathology, University of Miami, Miami, FL, USA.
Jose M Martinez-NavioDepartment of Pathology, University of Miami, Miami, FL, USA.ORCID 0000-0003-0560-5407
Matthew R GardnerDepartment of Medicine, Division of Infectious Disease, Emory University, Atlanta, GA, USA.ORCID 0000-0003-2872-7597
Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, Davis, CA, USA.ORCID 0000-0002-7375-1337
Diogo M MagnaniNonhuman Primate Reagent Resource, UMass Chan Medical School, Worcester, MA, USA.ORCID 0000-0002-1773-2406
Jeffrey D LifsonAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Guangping GaoDepartment of Genetic and Cellular Medicine, UMass Chan Medical School, Worcester, MA, USA.ORCID 0000-0003-0097-9012
Michael FarzanDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA.ORCID 0000-0002-2990-5319
Ronald C DesrosiersDepartment of Pathology, University of Miami, Miami, FL, USA.
Jishnu DasCenter for Systems Immunology, Departments of Immunology and Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0002-5747-064X
Mauricio A MartinsDepartment of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology, University of Florida, Jupiter, FL, USA. mauricio.martins@ufl.edu.ORCID 0000-0001-8336-216X
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · 2019 to 2025
$3932.6MNational Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5MTulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4MUniversity of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE · 2007 to 2026
$33.8MNonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1MProject 4: A permanent off-switch for AAVU19AI149646 · NIAID · UNIVERSITY OF FLORIDA · PI FARZAN, MICHAEL R. · 2020 to 2024
$14.0MAAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infectionR01HD102252 · NICHD · UNIVERSITY OF FLORIDA · PI MARTINS, MAURICIO DE AGUIAR · 2020 to 2024
$4.1MeCD4-Ig for preventing and treating obstetric HIV infectionR01HD103494 · NICHD · UNIVERSITY OF FLORIDA · PI MARTINS, MAURICIO DE AGUIAR · 2020 to 2024
$4.0MEngineering CAR-B cells for an HIV-1 functional cureR01DA056771 · NIDA · UNIVERSITY OF FLORIDA · PI Michael R. Farzan · 2022 to 2026
$3.5MOvercoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapiesR01AI175007 · NIAID · UNIVERSITY OF FLORIDA · PI Mauricio A Martins · 2023 to 2026
$3.5MNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI175007NIAID NIH HHS U19 AI149646NIAID NIH HHS U24 AI126683NICHD NIH HHS R01 HD102252NICHD NIH HHS R01 HD103494NIDA NIH HHS R01 DA056771NIH HHS P51 OD011104NIH HHS P51 OD011107
Abstract
Despite advances in HIV-1 prophylaxis, vertical transmission remains a pressing problem in developing countries
Indexed as
Antibodies, NeutralizingDependovirusGenetic VectorsHIV-1HIV AntibodiesHIV InfectionsMacaca mulattaAge FactorsAnimalsAnimals, NewbornFemaleHumansImmune ToleranceInfectious Disease Transmission, VerticalMaleSimian Acquired Immunodeficiency SyndromeAntibodies, NeutralizingHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.